PFG Investments LLC Cuts Stock Position in Aldeyra Therapeutics, Inc. $ALDX

PFG Investments LLC cut its holdings in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 74.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,000 shares of the biotechnology company’s stock after selling 191,300 shares during the quarter. PFG Investments LLC’s holdings in Aldeyra Therapeutics were worth $345,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ALDX. Y Intercept Hong Kong Ltd purchased a new stake in shares of Aldeyra Therapeutics during the third quarter worth about $721,000. Strs Ohio boosted its stake in Aldeyra Therapeutics by 4.1% in the 3rd quarter. Strs Ohio now owns 85,700 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 3,400 shares during the period. Inscription Capital LLC purchased a new stake in Aldeyra Therapeutics during the 3rd quarter valued at approximately $66,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Aldeyra Therapeutics by 20.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 32,842 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 5,556 shares during the last quarter. Finally, CWM LLC raised its position in shares of Aldeyra Therapeutics by 39.8% during the third quarter. CWM LLC now owns 58,379 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 16,621 shares during the last quarter. Institutional investors own 59.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ALDX shares. BTIG Research restated a “buy” rating and set a $9.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, November 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Aldeyra Therapeutics has an average rating of “Hold” and an average target price of $9.50.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX opened at $5.42 on Thursday. The stock has a 50 day moving average price of $4.90 and a 200-day moving average price of $5.16. Aldeyra Therapeutics, Inc. has a one year low of $1.14 and a one year high of $7.20. The company has a market capitalization of $326.07 million, a P/E ratio of -7.42 and a beta of 0.86.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. As a group, equities analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.